Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
作者: J. Connor WellsJeffrey GrahamBenoit BeuselinckGeorg A. BjarnasonFrede DonskovAaron R. HansenRana R. McKayUlka VaishampayanGuillermo De VelascoMei S. DuhLynn HuynhCatherine NguyenGiovanni ZanottiKrishnan RamaswamyToni K. ChoueiriDaniel Y.C. Heng
作者单位: 1Department of Oncology, University of Calgary, Calgary, AB, Canada
2Department of Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada
3Department of Oncology, University Hospital Leuven, Kathoieke Universiteit Leuven, Leuven, Belgium
4Department of Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
5Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
6Department of Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada
7Department of Oncology, University of California, San Diego, San Diego, CA
8Department of Oncology, Karmanos Cancer Institute, Detroit, MI
9Department of Oncology, University Hospital 12 de Octubre, Madrid, Spain
10Analysis Group, Inc, Boston, MA
11Pfizer, Inc, New York, NY
12Department of Oncology, Dana-Farber Cancer Institute, Boston, MA
刊名: Clinical Genitourinary Cancer, 2019
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2019.12.007
关键词: MRCCReal-world effectivenessSubsequent treatmentTargeted therapyTreatment outcomes
英文摘要: Abstract(#br)Background(#br)The present retrospective, longitudinal cohort study assessed the association between the first-line sunitinib treatment duration and clinical outcomes with second-line immuno-oncology (IO) therapy among patients with metastatic renal cell carcinoma (mRCC).(#br)Patients and Methods(#br)A total of 161 patients with mRCC who had been treated with first-line sunitinib and subsequent IO therapy from select International mRCC Database Consortium centers were included. The overall survival, time to next therapy, time to treatment discontinuation, and real-world physician-assessed best response measured from IO therapy initiation were analyzed and compared between patients treated with first-line sunitinib for ≥ 6 months and those treated for < 6...
全文获取路径: Elsevier  (合作)
影响因子:1.429 (2012)

  • oncology 肿瘤学